Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Roger Adsett Biography and Net Worth

COO of Insmed

Roger joined Insmed in September of 2016 as Chief Commercial Officer, and in November 2019 was appointed Chief Operating Officer. Prior to Insmed, Roger held various leadership roles with Shire from 2005 to 2016. During his time as senior vice president of its gastrointestinal and internal medicine business unit, Roger oversaw global commercial P&L across six specialty and two rare disease brands within his BU. Previously, he served as Shire’s gastrointestinal business unit leader, responsible for building a leading GI specialty business. Before Shire, Roger worked at AstraZeneca for 11 years in a variety of commercial positions, including marketing director for the US launch of Nexium®, a medicine for the treatment of gastroesophageal reflux disease (GERD), and the global brand director for Symbicort®, a medicine for the treatment of asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, Roger spent three years at Accenture. Roger holds a Master of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University.

What is Roger Adsett's net worth?: The estimated net worth of Roger Adsett is at least $10.93 million as of May 14th, 2024. Mr. Adsett owns 155,220 shares of Insmed stock worth more than $10,933,697 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Adsett may own. Learn More about Roger Adsett's net worth.
How old is Roger Adsett?: Mr. Adsett is currently 50 years old. There are 3 older executives and no younger executives at Insmed. Learn More on Roger Adsett's age.
How do I contact Roger Adsett?: The corporate mailing address for Mr. Adsett and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Roger Adsett's contact information.
Has Roger Adsett been buying or selling shares of Insmed?: Roger Adsett has not been actively trading shares of Insmed within the last three months. Most recently, Roger Adsett sold 7,857 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $25.50, for a transaction totalling $200,353.50. Following the completion of the sale, the chief operating officer now directly owns 155,220 shares of the company's stock, valued at $3,958,110. Learn More on Roger Adsett's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 534,475 shares worth more than $24,993,111.53. The most recent insider tranaction occured on December, 19th when CEO William Lewis sold 18,750 shares worth more than $1,310,812.50. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 12/19/2024.

Roger Adsett Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2024	Sell	7,857	$25.50	$200,353.50	155,220
1/12/2024	Sell	5,251	$28.63	$150,336.13	148,559
1/9/2024	Sell	3,837	$29.25	$112,232.25	157,346
1/5/2024	Sell	3,042	$29.21	$88,856.82	161,183
6/13/2023	Sell	8,981	$19.32	$173,512.92	151,352
1/10/2023	Sell	3,194	$17.99	$57,460.06	135,487
1/5/2023	Sell	3,044	$19.75	$60,119.00	131,083
11/22/2022	Sell	11,855	$18.80	$222,874.00	134,127
1/12/2022	Sell	1,217	$24.58	$29,913.86
1/5/2022	Sell	3,068	$27.61	$84,707.48
11/1/2018	Buy	3,000	$15.97	$47,910.00	18,594

Roger Adsett Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $70.44

$68.80

$71.07

50 Day Range

MA: $72.36

$66.29

$76.65

2 Week Range

Now: $70.44

$21.92

$80.53

Volume

5,932,421 shs

Average Volume

2,217,081 shs

Market Capitalization

$12.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Most People Are Dead Wrong.

From Brownstone Research | Ad